A5078220879- Cardiac Valve Diseases and Treatments
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Peripheral Artery Disease Management
- Coronary Interventions and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiovascular Disease and Adiposity
- Cerebrovascular and Carotid Artery Diseases
- Vascular Procedures and Complications
- Cardiac, Anesthesia and Surgical Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Muscle and Compartmental Disorders
- Pulmonary Hypertension Research and Treatments
- Cardiac and Coronary Surgery Techniques
- Diabetic Foot Ulcer Assessment and Management
- Aortic aneurysm repair treatments
- Gastrointestinal Tumor Research and Treatment
- Kawasaki Disease and Coronary Complications
- Sarcoidosis and Beryllium Toxicity Research
- Spondyloarthritis Studies and Treatments
- Blood properties and coagulation
- Viral Infections and Immunology Research
- Pelvic and Acetabular Injuries
- IgG4-Related and Inflammatory Diseases
Mie University Hospital
2022-2024
Mie University
2015-2024
Mitsui Memorial Hospital
2018-2019
Saitama Medical University
2018-2019
Doai Memorial Hospital
2019
Social Insurance Saitama Chuo Hospital
2018
Sakakibara Hospital
2015
Kansai Rosai Hospital
2012-2013
Malignancy is common in older adults undergoing transcatheter aortic valve implantation (TAVI), and may affect prognosis. The present study aimed to examine whether active cancer affects all-cause mortality rates among patients TAVI.This retrospective examined data from 1,114 consecutive treated between April 2010 June 2019. Patients with life expectancy of <1 year due non-cardiac causes were excluded.Active was defined as under treatment or cured within 1 year, recognized 62 (5.6%) (n = 17)...
Background The Japan Arteriosclerosis Longitudinal Study-Existing Cohorts Combine (JALS-ECC) is a pooled study based on individual participant data from existing prospective cohort studies in Japan. Its purpose was to consider associations between risk factors and cardiovascular disease (CVD) outcomes, as well differences subgroups, defined by age, gender or geographical region, which could not be detected the smaller samples. Methods Results Individual records for 66,691 participants 21...
Obesity has previously been identified as an indicator of good prognosis in patients undergoing transcatheter aortic valve implantation (TAVI), association known the "obesity paradox". We investigated whether abdominal total fat area (TFA), visceral (VFA), or subcutaneous (SFA) are prognostic indicators long-term clinical outcome TAVI. Methods and Results: retrospectively analyzed 100 consecutive who underwent TAVI between December 2013 April 2017. TFA, VFA, SFA were measured from routine...
Obesity is a major risk factor for cardiovascular disease; however, paradoxical effect of obesity has been reported in patients with heart failure or myocardial infarction. Although several studies have suggested the same paradox undergoing transcatheter aortic valve replacement (TAVR), they included limited number underweight patients.This study aimed to clarify being on TAVR outcomes.We retrospectively analyzed 1,693 consecutive between 2010 and 2020. The were categorized according body...
A history of hospitalization for heart failure (HHF) before transcatheter aortic valve implantation (TAVI) or surgical replacement is associated with the prognosis patients severe stenosis (AS). However, impact prior HHF on clinical outcomes after contemporary TAVI using new-generation valves (THVs) has not been thoroughly investigated.
Information regarding the outcomes of transcatheter aortic valve replacement (TAVR) in men is limited. This study aimed to investigate short- mid-term and prognostic predictors this population. The data 519 were analyzed from 1,693 consecutive patients with symptomatic severe stenosis who underwent TAVR at six hospitals between April 2010 July 2020. primary endpoint was all-cause mortality 30 days after TAVR. mean age Society Thoracic Surgeons (STS) score 83.7 ± 5.9 years 6.3 4.7%,...
Pulmonary hypertension (PH) is a common complication of aortic stenosis (AS). Despite the established association between PH and poor outcomes in patients with AS, prognostic implication change after transcatheter valve implantation (TAVI) has been rarely evaluated. This study analyzed prospective multi-center TAVI registry database involving six Japanese centers used transtricuspid pressure gradient (TRPG) obtained by echocardiography to estimate pulmonary artery systolic pressure. The...
Abstract Background Transcatheter aortic valve implantation (TAVI) is considered an established treatment option for patients with severe stenosis. When implanting self-expandable valve, pre-dilatation often necessary to facilitate optimal transcatheter heart (THV) deployment. Traditionally, balloon sizes chosen are smaller than the minimum annulus diameter. Insufficient can result in under-expansion of THV, necessitating post-dilatation, and increase risk complications. However, this...
Abstract Backgrounds: Transcatheter aortic valve implantation (TAVI) is now a cornerstone treatment for symptomatic severe stenosis across all risk profiles, including low-risk and younger patients. As such, the performance durability of transcatheter heart valves (THVs) are paramount. SAPIEN3 Ultra RESILIA (S3 UR) expected to improve hemodynamics compared with (S3) due use bovine pericardial tissue modified sawing maneuvers each three leaflets in 20 23mm valves. Aim The aim study was...
末期腎不全で維持血液透析中の55歳男性が.左重症下肢虚血に対して繰り返し血管内治療を施行されていた.左足の感染の増悪で入院となり,抗生剤加療が開始された.左第3から5趾の重症下肢虚血に対して第7病日よりACE阻害薬を中止し第10病日より吸着式潰瘍治療法レオカーナ®を施行した.開始後6分で血圧低下を認めレオカーナ®中止と生理食塩水の補液を行ったがショック状態が持続した.ノルアドレナリン投与にてショック状態から離脱したが10時間後まで低血圧が持続した.レオカーナ®とACE阻害薬の併用はブラジキニンによるショック状態が出現する懸念があり禁忌である.メーカーから1か月前からの休薬期間が推奨されているものの明確な中止基準が存在しない.本症例ではレオカーナ®施行3日前よりACE阻害薬を中止としたがショック状態が出現し遷延した.レオカーナ®を施行する際のACE阻害薬の中止期間には特段の注意が必要であり報告する.